Isohexadecyl 12-[(1-oxooctadecyl)oxy]octadecanoate

Endpoint summary

Description of key information

Oral: OECD 407, rat, NOAEL ≥ 1000 mg/kg bw/day

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

17 Mar - 14 Apr 1998

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))

Deviations:

no

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

Wistar

Remarks:

Wistar Crl:(WI) BR

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River, Sulzfeld, Germany
- Age at study initiation: approximately 6 weeks
- Weight at study initiation: 185-208 g (males); 153-173 g (females)
- Fasting period before study: no
- Housing: the animals were housed in groups of 5 per sex per cage in stainless steel suspended cages with wire mesh floors. During activity monitoring, animals were individually housed overnight in Macrolon plastic cages with sterilised sawdust (B.M.I. Helmond, the Netherlands) provided as bedding.
- Diet: standard pelleted laboratory animal diet (Carfil Quality BVBA, Oud-Turnhout, Belgium), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 (optimal temperature)
- Humidity (%): 50 (optimal humidity level)
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 17 Mar 1998 To: 14 Apr 1998

Route of administration:

oral: gavage

Vehicle:

corn oil

Details on oral exposure:

PREPARATION OF DOSING SOLUTIONS:
Formulations (w/w) were prepared daily within 4 hours prior to dosing and placed on a magnetic stirrer during dosing. Adjustment was made for the specific gravity of test substance and vehicle. The solution was shown to be stable for at least 4 hours.

VEHICLE
- Justification for use and choice of vehicle (if other than water): the vehicle choice was based on trial formulations performed at the test laboratory
- Concentration in vehicle: 10, 40 and 200 mg/mL
- Amount of vehicle (if gavage): 5 mL/kg bw

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

GC-analyses were performed to determine the concentration of the test material of all dosing solutions. The actual concentrations were shown to be 95-107% of the nominal concentration, as analysed in duplicate samples. The homogeneity of the low- and high concentration samples was measured in duplicate samples. The concentration as sampled at 10, 50 and 90% height was shown to be 97-106% of nominal values. A relative difference of -2.8 - 2.1% in the stability from t=o to t=4 hours was measured in duplicate samples.

Duration of treatment / exposure:

28 days

Frequency of treatment:

Once daily, 7 days/week

Dose / conc.:

50 mg/kg bw/day (actual dose received)

Remarks:

administered by gavage, calculated weekly according to body weight

Dose / conc.:

200 mg/kg bw/day (actual dose received)

Remarks:

administered by gavage, calculated weekly according to body weight

Dose / conc.:

1 000 mg/kg bw/day (actual dose received)

Remarks:

administered by gavage, calculated weekly according to body weight

No. of animals per sex per dose:

5

Control animals:

yes, concurrent vehicle

Details on study design:

- Dose selection rationale: a range-finding study was performed with 3 rats/sex/dose, administered 0, 50 200 and 1000 mg/kg bw/day for 5 days (report No. 227306). There was no mortality. No treatment-related clinical signs were observed, no effect on body weight or food consumption was noted, there were no macroscopic findings, and the liver and kidney weights were comparable to those of the control group. Therefore, the same dose levels were selected for the main study.

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: the animals were observed for mortality twice daily and for clinical signs once daily

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: on Day 8, 15, 22 and 28, detailed clinical observations were made outside the cage in a standard arena. Symptomes were recorded and graded according to a fixed scale.

BODY WEIGHT: Yes
- Time schedule for examinations: body weights were recorded on Day 1, 8, 15, 22 and 28 of the study

FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes. Food consumption was measured weekly.

FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No

WATER CONSUMPTION: No

OPHTHALMOSCOPIC EXAMINATION: No

HAEMATOLOGY: Yes
- Time schedule for collection of blood: immediately prior to scheduled necropsy
- Anaesthetic used for blood collection: Yes; ether
- Animals fasted: Yes, overnight for a maximum of 20 hours, with free access to water
- How many animals: all the animals in the control and treatment groups
- Parameters checked: erythrocytes, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, red cell distribution width, total leucocyte count, differential leucocyte count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), prothrombin time, partial thromboplastin time

CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: immediately prior to scheduled necropsy
- Animals fasted: Yes, overnight for a maximum of 20 hours, with free access to water
- How many animals: all the animals in the control and treatment groups
- Parameters checked: alanine aminotransferase, aspartate aminotransferase, bilirubin, cholesterol, creatinine, glucose, urea, total protein, albumin, alkaline phosphatase, sodium, potassium, chloride, calcium, inorganic phosphorus

URINALYSIS: No

NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: during week 4 of the treatment
- Dose groups that were examined: the control group and all treatment groups
- Battery of functions tested: hearing ability, pupillary reflex, static righting reflex, grip strength, activity test (based on hourly data per animal, using a computerised motor activity monitoring system)

Sacrifice and pathology:

GROSS PATHOLOGY: Yes. All the animals in the control and treatment groups were necropsied and a description of all macroscopic abnormalities was recorded. Samples of the following tissues and organs were collected from all animals at necropsy and fixed in neutral phosphate buffered 4% formaldehyde solution:
adrenal glands, aorta, brain, caecum, cervix, clitoral gland, colon, duodenum, epididymides, eyes with optic nerve and Harderian gland, female mammary glandarea, femur including joint, heart, ileum, jejunum, kidneys, larynx, lacrimal gland (exorbital), liver, lung (infused with formalin), lymph nodes (mandibular, mesenteric), nasopharynx, oesophagus, ovaries, pancreas, Peyer's patches (jejunum, ileum, if detectable), pituitary gland, preputial gland, prostate, rectum, salivary glands (mandibular, sublingual), sciatic nerve, seminal vesicles, sceletal muscle, skin, spinal cord (cervical, midthoracic, lumbar), spleen, sternum with bone marrow, stomach, testes, thymus, thyroid including parathyroid, tongue, trachea, urinary bladder, uterus, vagina, all gross lesions.

The following organ weights were recorded from the surviving animals on the scheduled day of necropsy: adrenal glands, brain,
epididymides, heart, kidneys, liver, spleen, testes, thymus.

HISTOPATHOLOGY: Yes. The organ and tissue samples were processed, embedded and cut at a thickness of 2.4 micrometers and stained with haematoxylin and eosin. For the control and 1000 mg/kg bw/day groups, the following organs were histologically examined: adrenal glands, aorta, brain, caecum, colon, duodenum, epididymides, heart, ileum, jejunum, kidneys, liver, lung (infused with formalin), lymph nodes (mandibular, mesenteric), oesophagus, ovaries, pancreas, Peyer's patches (jejunum, ileum, if detectable), pituitary gland, preputial gland, prostate, rectum, sciatic nerve, spinal cord (cervical, midthoracic, lumbar), spleen, sternum with bone marrow, stomach, testes, thymus, thyroid including parathyroid, trachea, urinary bladder, uterus. The organs and tissues that were preserved but not examined during histopathology did not show signs of toxicity or other effects. The observed gross lesions were examined in animals from all the groups.

Statistics:

The following statistical methods were used to analyse the data: Univariate one-way analysis of variance was used to assess the significance of intergroup differences. If the variables could be assumed to follow a normal distribution, the Dunnett test (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex. The Steel-test (many-to-one rank test) was applied when the data could not be assumed to follow a normal distribution. All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance. Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances.

Clinical signs:

effects observed, treatment-related

Description (incidence and severity):

50 mg/kg bw/day: females, salivation (non-adverse)

Mortality:

mortality observed, treatment-related

Description (incidence):

50 mg/kg bw/day: females, salivation (non-adverse)

Body weight and weight changes:

no effects observed

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

effects observed, treatment-related

Description (incidence and severity):

1000 mg/kg bw/day: females, increase relative leucocyte level, decrease relative neutrophil level (non-adverse)

Clinical biochemistry findings:

effects observed, treatment-related

Description (incidence and severity):

1000 mg/kg bw/day: males, increased chloride level, increased calcium level (non-adverse)

Urinalysis findings:

not examined

Behaviour (functional findings):

no effects observed

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

not examined

Details on results:

CLINICAL SIGNS AND MORTALITY
There was no mortality during the study period. No treatment-related clinical signs were observed in any group. Salivation was observed on one or several days in 1/5 males and 1/5 females in the low-dose group, and 2/5 males and 1/5 females in the high-dose group (see Table 1). As there is no dose-response effect and no other clinical or neurological signs that indicate that the effect is treatment-related, this is considered to be an incidental finding, which is probably caused by the administration procedure. Incidental observations of alopecia, red staining, piloerection and scabs were made, involving one or several animals. These findings are considered to be within the expected range for rats of this age and strain and regularly occur during a subacute study.

BODY WEIGHT AND WEIGHT GAIN
No significant differences in body weight or body weight gain were observed between the control and treatment groups.

FOOD CONSUMPTION
No significant differences in food consumption were observed between the control and treatment groups.

HAEMATOLOGY
In females of the high-dose group, a statistically significant increase in relative leucocyte level (app. 8%) and decrease in relative neutrophil level (app. 8%) was noted, compared with the control group values. These values are related to each other as a percentage of the total lymphocyte concentration, and a variation in one will necessarily affect one or several other specific lymphocyte values. As the changes are minimal, no effects were seen in males and no other haematological effects were noted, this effect may be treatment-related, but is considered not to be of toxicological relevance.

CLINICAL CHEMISTRY
In males of the high-dose group, the level of calcium and chloride was significantly increased. As these increases were around 5% compared with the control group levels and no similar effects were observed in the female groups they are not considered be of toxicological relevance. The statistically significant change in bilirubin level in mid-dose males is considered to be incidental, as no effect was seen in the highest dose level and the mean value was the same in all male groups.

NEUROBEHAVIOUR
1/5 females in the control group showed a statistically significant increase in motor activity. This is considered to be an incidental occurrence as no other animals exhibited the same behaviour. No treatment-related effects were observed.

ORGAN WEIGHTS
There were no statistically significant differences in absolute or relative organ weight in the treatment groups, compared to the control group.

GROSS PATHOLOGY
No treatment-related findings were reported. In 2/5 females in the mid-dose group watery fluid was observed in the uterus. This is a normal finding during a part of the estrus cycle in rats.

HISTOPATHOLOGY: NON-NEOPLASTIC
There were no treatment-related histopathological findings. The incidence and severity of the observed lesions were similar in the control group and treatment groups and are considered to have occured spontaneously.

Key result

Dose descriptor:

NOAEL

Effect level:

>= 1 000 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: No treatment-related effects were observed up to and including the highest dose level

Key result

Critical effects observed:

no

Table 1: Clinical signs; salivation observed as number of rats per group and days per rat

Group (mg/kg bw/day)	Control	50	200	1000
Males (No. - days observed)	0	1 (Day 9)	0	2 (Day 9 and Day 9, 27-28)
Females	0	1 (Day 27-28)	0	2 (both Day 26-28)

Table 2: Haematology results

	Group (mg/kg bw/day)
	Males				Females
	Control	50	200	1000	Control	50	200	1000
Neutrophils (1)^1	0.093 ± 0.022	0.108 ± 0.049	0.116 ± 0.021	0.090 ± 0.047	0.138 ± 0.022	0.079 ± 0.031	0.115 ± 0.023	0.063 ± 0.018*
Lymphocytes (1)^1	0.883 ± 0.026	0.862 ± 0.053	0.851 ± 0.040	0.872 ± 0.056	0.830 ± 0.027	0.891 ± 0.027	0.851 ± 0.029	0.908 ± 0.027*
WBC (G/L)	13.5 ± 3.2	12.5 ± 0.5	12.1 ± 2.4	13.6 ± 2.7	7.7 ± 1.9	8.0 ± 1.8	8.2 ± 3.6	7.8 ± 1.9

*Statistically significant (p < 0.05)

¹relative part of total =1

 

Table 3: Clinical chemistry results

	Group (mg/kg bw/day)
	Males				Females
	Control	50	200	1000	Control	50	200	1000
Calcium (mmol/L)	2.53 ± 0.04	2.52 ± 0.04	2.52 ± 0.02	2.44 ± 0.02*	2.49 ± 0.07	2.47 ± 0.06	2.52 ± 0.05	2.47 ± 0.05
Chloride (mmol/L)	101 ± 2	100 ± 1	99 ± 2	97 ± 1**	98 ± 2	100 ± 2	100 ± 1`	98 ± 2

*Statistically significant (p < 0.05)

**Statistically significant (p < 0.01)

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

The available information comprises adequate, reliable (Klimisch score 2 due to read-across) and consistent studies from reference substances with similar structure and intrinsic properties. Read-across is justified based on common precursors and breakdown products of hydrolysis and consistent trends in environmental fate, ecotoxicological and toxicological profile (refer to the endpoint discussion for further details).
The selected study is thus sufficient to fulfil the standard information requirements set out in Annex VIII, 8.6, in accordance with Annex XI, 1.5, of Regulation (EC) No 1907/2006.

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

Justification for read-across

There are no available data on the repeated dose toxicity of Isohexadecyl 12-[(1-oxooctadecyl)oxy]octadecanoate (CAS 97338-28-8). The assessment was therefore based on studies conducted with analogue substances as part of a read across approach, which is in accordance with Regulation (EC) No. 1907/2006, Annex XI, 1.5. For each specific endpoint the source substance(s) structurally closest to the target substance is/are chosen for read-across, with due regard to the requirements of adequacy and reliability of the available data. Structural similarities and similarities in properties and/or activities of the source and target substance are the basis of read-across. A detailed justification for the analogue read-across approach is provided in the technical dossier (see IUCLID Section 13).

Repeated dose toxicity, oral, subacute

CAS 93803-87-3

A 28-day oral repeated dose toxicity study was performed according to OECD 407 and under GLP conditions, using Octyldodecyl isooctadecanoate (key, 1998). 5 Wistar rats/sex/dose were administered 0, 50, 200 and 1000 mg/kg bw/day by gavage, for 28 consecutive days. There was no mortality and no toxicologically relevant clinical signs were observed during the study period. No significant differences in body weight, body weight gain and food consumption between the control group and treatment groups were noted. In females of the high-dose group, a statistically significant increase in relative leucocyte level (approximately 8%) and decrease in relative neutrophil level (app. 8%) was noted, compared with the control group values. These values are related to each other as a percentage of the total lymphocyte concentration, and a variation in one will necessarily affect one or several other specific lymphocyte values. As the changes are minimal, no effects were seen in males and no other haematological effects were noted, this result is considered not have toxicological relevance. In males of the high-dose group, the level of calcium and chloride was significantly increased. These increases were around 5% compared with the control group levels and no similar effects were observed in the female groups. Therefore, they are not considered to have toxicological relevance. No treatment-related effects on neurobehavioural parameters were observed. There were no significant differences in absolute or relative organ weight in the treatment groups, compared to the control group. The macroscopic inspection at autopsy and subsequent histopathological examination did not reveal any treatment-related changes. Based on the lack of toxicologically relevant effects up to and including the highest dose level, the NOAEL is considered to be ≥ 1000 mg/kg bw/day.

CAS 17671-27-1

In a combined repeated dose toxicity and reproduction/developmental toxicity screening study performed according to OECD guideline 422 under GLP conditions, the potential adverse effects of Docosyl docosanoate were assessed (supporting A, 2014). 10 rats/dose/day were administered 0, 100, 300 and 1000 mg/kg bw/day Docosyl docosanoate once daily via gavage up to day 49 of treatment (males) or day 4 postpartum (females). The application started two weeks before mating on test day one and ended one day before sacrifice. No test item-related premature death was noted. No test item-related signs of toxicity were noted during the observational and neurological screenings. A treatment-related decrease in body weight was noted for the female animals of the high dose group (1000 mg /kg bw/day) on lactation day 4. No toxicologically relevant effects were observed on the haematological and clinical chemistry parameters. The macroscopic inspection at autopsy and subsequent histopathological examination did not show any treatment-related changes. The NOAEL for systemic toxicity was determined to be ≥ 1000 mg/kg bw/day in this study.

CAS 22393-85-7

A combined repeated dose toxicity and reproduction/developmental toxicity screening study was performed according to OECD guideline 422 and in compliance with GLP (supporting B, 2014). 10 rats/sex/dose were administered 0, 100, 300 and 1000 mg/kg bw/day Tetradecyl oleate once daily for 28-29 days (males) and up to 54 days (females) via gavage. The application started two weeks before mating on test day one and ended on the day of or one day before sacrifice. Day of sacrifice was on test day 29 or 30 for the male rats and on lactation day 3 or shortly thereafter for the female rats. There was no mortality during the study period. No toxicologically relevant clinical signs were observed. The body weight, body weight gain and food consumption was comparable between the control and treatment groups. There were no toxicologically relevant effects on organ weights. The statistically significant differences in haematological parameters between control and treated animals (erythrocytes, mean corpuscular haemoglobin and leucocytes in males, haemoglobin, haematocrit and platelets in females) were of low magnitude and/or not dose-related, and therefore considered incidental. Statistically significant fluctuations of some biochemical parameters, compared with the control groups, were recorded in both sexes. An increase in glucose levels in males administered 100 and 1000 mg/kg bw/day (48% for both doses), and an increase in urea in males receiving 100 mg/kg bw/day (19%) was observed. In females in the 300 mg/kg bw/day group, an increase in aspartate aminotransferase level (35%) was noted, while for females administered 1000 mg/kg bw/day, a decrease in bilirubin levels (81%) and an increase in potassium levels (10%) were observed. Due to the lack of dose- and/or sex-consistency, and due to the absence of other relevant findings, these changes are not considered to be toxicologically relevant. There was no significant difference between control and treatment groups during the observational and neurological screenings. The macroscopic inspection at autopsy and subsequent histopathological examination did not show any treatment-related changes. The NOAEL for systemic toxicity was considered to be ≥ 1000 mg/kg bw/day.

 

Overall conclusion for repeated dose toxicity

Analogue read-across from subacute studies from 3 source substances was applied to assess the potential for the target substance to causerepeated dose toxicity. The NOAEL values for repeated dose toxicity were at or above the currently applied limit dose value of 1000 mg/kg bw/day. No hazard after repeated oral exposure was identified. Therefore, Isohexadecyl 12-[(1-oxooctadecyl)oxy]octadecanoate is not expected to cause long-term toxic effects via the oral route.

Justification for classification or non-classification

According to Article 13 of Regulation (EC) No. 1907/2006 "General Requirements for Generation of Information on Intrinsic Properties of substances", information on intrinsic properties of substances may be generated by means other than tests e.g. from information from structurally related substances (grouping or read-across), provided that conditions set out in Annex XI are met. Annex XI, "General rules for adaptation of this standard testing regime set out in Annexes VII to X” states that “substances whose physicochemical, toxicological and ecotoxicological properties are likely to be similar or follow a regular pattern as a result of structural similarity may be considered as a group, or ‘category’ of substances. This avoids the need to test every substance for every endpoint". Since the analogue concept is applied to Isohexadecyl 12-[(1-oxooctadecyl)oxy]octadecanoate (CAS 97338-28-8), data will be generated from data for reference source substance(s) to avoid unnecessary animal testing. Additionally, once the analogue read-across concept is applied, substances will be classified and labelled on this basis.

Therefore, based on the analogue read-across approach, the available data on repeated dose toxicity do not meet the classification criteria according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification.